E. Mckone

A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Matthias Griese, P. Dřevínek, N. McElvaney, 2011, The New England journal of medicine.

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections

C. Goss, M. Welsh, S. Salipante, 2021, mBio.

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis.

E. Mckone, J. Eustace, D. Bilton, 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

The future of cystic fibrosis care: a global perspective.

C. Goss, P. Burgel, M. Macek, 2020, The Lancet. Respiratory medicine.

Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020

M. Mei-Zahav, P. Yiallouros, P. Burgel, 2021, Journal of Cystic Fibrosis.

CFTR genotype as a predictor of prognosis in cystic fibrosis.

C. Goss, E. Mckone, M. Aitken, 2006, Chest.

Correlation between Ivacaftor-induced CFTR Activation in Airway Epithelial Cells and Improved Lung Function: A Proof-of-Concept.

E. Mckone, Pradeep K. Singh, K. Barrow, 2020, Annals of the American Thoracic Society.

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

E. Ingenito, E. Mckone, A. Munck, 2017, The New England journal of medicine.

Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.

L. Lands, D. Waltz, P. Dřevínek, 2019, The New England journal of medicine.